Novartis Ag

Claus Erhardt

Werner Breitenstein

Keiichi Masuya

Nils Ostermann

Philipp Grosche

Edgar Jacoby

Fumiaki Yokokawa

Juergen Klaus Maibaum

Andreas Marzinzik

Takanori Kanazawa

Kazuhide Konishi

Shimpei Kawakami

Juerg Zimmermann

The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The preferred compounds (which can also be present as salts) have the formula I wherein R1, R2, T, R3 and R4 are as defined in the specification. 

Organic compounds

Growing community of inventors

Lörrach, Germany

Claus Erhardt